Key facts
- This page summarizes W. Thorpe McKenzie's Form 4 filing for XBiotech Inc. (XBIT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2024, 14:16.
W. Thorpe McKenzie - 20 Jun 2024 Form 4 Insider Report for XBiotech Inc. (XBIT)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- XBIT
- Reported as of
- 20 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2024, 14:16:44 UTC
- Prior SEC filing
- 26 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /S/ Angela Hu under Power of Attorney for W.Thorpe McKenzie
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
W. Thorpe McKenzie filed Form 4 for XBiotech Inc. (XBIT) on 21 Jun 2024.
Change
- Previous filing in this sequence was filed on 26 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XBIT
transaction
Derivative
Director Stock Option
Award
- Transaction value
- $0
- Shares
- +37,500
- Change %
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 20 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,500
- Exercise price
- $5.12
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
On June 20, 2024 (the Grant Date) the reporting person was granted nonstatutory stock options (the Options) under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock (the Shares) at an exercise price equal to the closing sales price of the Shares on the Grant Date as quoted by the Nasdaq Stock Market. The Options vest in two equal portions at six month and one year from the Grant Date with an expiry of ten years from the Grant Date.